Optimization Of HIV Specific Immune Responses In Vivo

HIV 体内特异性免疫反应的优化

基本信息

项目摘要

Successful development of a vaccine against HIV will likely require the induction of both antibody and/or cellular immune responses sufficient to prevent infection or disease respectively following infectious challenge. While the induction of antibody responses for a variety of other infectious pathogens is readily achieved by a variety of vaccine formulations, live attenuated, recombinant viral vaccines or plasmid DNA vaccines only induce the induction of long-lived cellular immune responses, particularly CD8+ T cell responses. Moreover, since live attenuated HIV vaccines might be precluded from use due to safety concerns and DNA vaccines at present only induce modest CD8+ T cell responses in humans, there is an urgent need to develop ways to enhance the generation and maintenance of CD8+ T cell responses in humans in following immunization. This study focuses on how to optimize the magnitude and duration of CD8+ T cell responses following vaccination in rodents and primates using a variety of vaccine formulations. The data obtained over this past year have shown the following; 1. Prime-boost immunization with SIV Gag protein and TLR 3 or 7/8 ligands elicit potent T cell responses in non-human primates. Such responses were noted in both peripheral blood mononuclear cells and were much higher in the broncheoalveolar lavage. Upon boosting with rAd-5 SIV , CD8+ T cell responses were further enhanced. Animals were challenged with SIV Mac 251. These results show that a heterologous prime-boost immunization regimen using a protein and TLR ligand followed by rAd-5 induces potent T cell immunity. 2. Experiments in NHP have compared HIV Gag DNA versus HIV Gag protein+ Poly I:C as a prime prior to rAd-5 Gag as a boost. The data reveals that priming with DNA enhances both CD4 and CD8 responses after the rAd5 HIV Gag boost compared to rAd5 HIV Gag alone. By contrast, priming with HIV Gag protein+ Poly I:C enhanced the magnitude of CD4 responses following the rAd5 boost but not CD8 responses. Moreover, it was notable that DNA immunization but not protein + Poly I:C induced a small frequency of CD8 cells after the priming. Collectively these data suggest that priming for CD8+ T cells is critical if there is to be further expansion of such cells after the boost.
成功开发针对HIV的疫苗可能需要诱导足以分别预防感染性攻击后的感染或疾病的抗体和/或细胞免疫应答。虽然通过多种疫苗制剂容易实现对多种其它感染性病原体的抗体应答的诱导,但是减毒活重组病毒疫苗或质粒DNA疫苗仅诱导长寿命细胞免疫应答的诱导,特别是CD 8 + T细胞应答。此外,由于减毒活HIV疫苗可能由于安全性问题而被排除使用,并且DNA疫苗目前仅在人体中诱导适度的CD 8 + T细胞应答,因此迫切需要开发在免疫后增强人体中CD 8 + T细胞应答的产生和维持的方法。这项研究的重点是如何优化CD 8 + T细胞反应的幅度和持续时间后,在啮齿动物和灵长类动物使用各种疫苗配方接种。 过去一年获得的数据表明: 1.用SIV Gag蛋白和TLR 3或7/8配体的初免-加强免疫在非人灵长类动物中引发有效的T细胞应答。在外周血单核细胞中均观察到这种反应,并且在支气管肺泡灌洗中更高。在用rAd-5 SIV加强后,CD 8 + T细胞应答进一步增强。用SIV Mac 251攻击动物。 这些结果表明,使用蛋白质和TLR配体,随后使用rAd-5的异源初免-加强免疫方案诱导有效的T细胞免疫。 2. NHP中的实验比较了HIV Gag DNA与HIV Gag蛋白+ Poly I:C作为初免,然后rAd-5 Gag作为加强。数据显示,与单独的rAd 5 HIV Gag相比,用DNA引发增强了rAd 5 HIV Gag加强后的CD 4和CD 8应答。相比之下,用HIV Gag蛋白+ Poly I:C引发增强了rAd 5加强后的CD 4应答的幅度,但不增强CD 8应答。此外,值得注意的是,DNA免疫而不是蛋白+ Poly I:C在引发后诱导了小频率的CD 8细胞。总的来说,这些数据表明,如果在加强免疫后要进一步扩增CD 8 + T细胞,那么对CD 8 + T细胞的引发是至关重要的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT A SEDER其他文献

ROBERT A SEDER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT A SEDER', 18)}}的其他基金

VACCINE DEVELOPMENT FOR TUBERCULOSIS
结核病疫苗的开发
  • 批准号:
    7958684
  • 财政年份:
    2009
  • 资助金额:
    $ 164.19万
  • 项目类别:
DNA VACCINATION FOR PREVENTION OF VIRAL, PARASITIC AND MYCOBACTERIAL INFECTION
用于预防病毒、寄生虫和分枝杆菌感染的 DNA 疫苗接种
  • 批准号:
    6288990
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Development Of A Vaccine For Leishmania Major Infection
开发利什曼原虫重大感染疫苗
  • 批准号:
    7299819
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Development Of A Vaccine For Leishmania Major Infection
开发利什曼原虫重大感染疫苗
  • 批准号:
    6987266
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Development Of A Vaccine For Leishmania Major Infection
开发利什曼原虫重大感染疫苗
  • 批准号:
    8745612
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Development Of A Vaccine For Leishmania Major Infection
开发利什曼原虫重大感染疫苗
  • 批准号:
    8556093
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Factors Regulating T Helper Cell Memory Differentiation
调节 T 辅助细胞记忆分化的因素
  • 批准号:
    6822221
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Optimization Of Hiv Specific Immune Responses In Vivo
体内 HIV 特异性免疫反应的优化
  • 批准号:
    6684235
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Development Of A Vaccine For Leishmania Major Infection
开发利什曼原虫重大感染疫苗
  • 批准号:
    6684236
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:
Development of Pre-Erythrocytic Malaria Vaccines and antibodies
前红细胞疟疾疫苗和抗体的开发
  • 批准号:
    10683005
  • 财政年份:
  • 资助金额:
    $ 164.19万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 164.19万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了